Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20270050 | 0.90 | HTR2A (0.43) | SLC6A4SRD5A1HTR2AHTR2CHTR2B | |
| SCHEMBL16146473 | 0.81 | POLB (0.39) | — | |
| SCHEMBL29700361 | 0.80 | LRRK2 (0.48) | — | |
| SCHEMBL22056586 | 0.79 | IDO1 (0.53) | HTR2AHTR2CHTR2BIDO1 | |
| SCHEMBL18106445 | 0.79 | KDM1A (0.34) | KDM1A | |
| SCHEMBL28327803 | 0.78 | CMA1 (0.37) | — | |
| SCHEMBL20449129 | 0.78 | ADRA2A (0.47) | ADRA2AAPLNR | |
| SCHEMBL20449128 | 0.78 | ADRA2A (0.47) | ADRA2AAPLNR | |
| SCHEMBL25622 | 0.78 | ALDH1A1 (0.32) | — | |
| SCHEMBL25621 | 0.78 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771332-B1 | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | MERCK CANADA INC (CA) | 2016-06-29 | — | — | EP | disclosed |
| US-9133157-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-09-15 | — | — | US | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-10-09 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| EP-1734966-A4 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009038411-A2 | BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY | LG LIFE SCIENCES, LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
| EP-1734966-A2 | PIPERIZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | Incyte Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005101838-A2 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, PRSS3 | SLC6A4 3893/4885SRD5A1 1117/4885HTR2A 4704/4885 |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | CCR5, CCR2, CXCR5 | SLC6A4 1798/4885SRD5A1 2001/4885HTR2A 565/4885 |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | SLC6A4 1798/4885SRD5A1 2001/4885HTR2A 565/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | SLC6A4 4558/4885SRD5A1 130/4885HTR2A 4425/4885 |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | SLC6A4 1798/4885SRD5A1 2001/4885HTR2A 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.